Suppliers / Pharmablock Pharmaceuticals (Zhejiang)

Pharmablock Pharmaceuticals (Zhejiang)

China Updated 9 July 2026

Pharmablock Pharmaceuticals (Zhejiang) is an API manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its most recent recorded inspection, by US FDA, closed on 5 July 2019 as NAI.

2
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 5 July 2019 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3003005071

What they file, and where

Molecule Regulators Docs
Guanfacine US FDA 1
Tofacitinib US FDA 1

Also appears on these molecule pages

Guanfacine API Tofacitinib API

Questions about Pharmablock Pharmaceuticals (Zhejiang)

Does Pharmablock Pharmaceuticals (Zhejiang) hold a US DMF or a CEP?
Pharmablock Pharmaceuticals (Zhejiang) holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Pharmablock Pharmaceuticals (Zhejiang) FDA-registered?
One site operated by Pharmablock Pharmaceuticals (Zhejiang) carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Pharmablock Pharmaceuticals (Zhejiang)'s last inspection go?
The most recent inspection on record closed on 5 July 2019 as NAI (No Action Indicated: nothing objectionable was found). 1 inspection is on file.
Where does Pharmablock Pharmaceuticals (Zhejiang) manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Pharmablock Pharmaceuticals (Zhejiang) make?
2 molecules are on record against Pharmablock Pharmaceuticals (Zhejiang), including Guanfacine and Tofacitinib. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Pharmablock Pharmaceuticals (Zhejiang) comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 5 July 2019.

Comparable suppliers

MSN Laboratories shares 1 molecule Dr Reddy's Laboratories shares 1 molecule Alivus Life Sciences shares 1 molecule Olon shares 1 molecule Matrix Pharmacorp shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability